 Hemorrhagic Fever, Ebola
"Hemorrhagic Fever, Ebola" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly fatal, acute hemorrhagic fever, clinically very similar to MARBURG VIRUS DISEASE, caused by EBOLAVIRUS, first occurring in the Sudan and adjacent northwestern (what was then) Zaire.
| Descriptor ID |
D019142
|
| MeSH Number(s) |
C02.782.417.415 C02.782.580.250.400
|
| Concept/Terms |
Hemorrhagic Fever, Ebola- Hemorrhagic Fever, Ebola
- Ebola Infection
- Infection, Ebola
- Ebola Virus Infection
- Infection, Ebola Virus
- Virus Infection, Ebola
- Ebola Hemorrhagic Fever
- Ebola Virus Disease
|
Below are MeSH descriptors whose meaning is more general than "Hemorrhagic Fever, Ebola".
Below are MeSH descriptors whose meaning is more specific than "Hemorrhagic Fever, Ebola".
This graph shows the total number of publications written about "Hemorrhagic Fever, Ebola" by people in this website by year, and whether "Hemorrhagic Fever, Ebola" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 2 | 1 | 3 | | 2007 | 3 | 0 | 3 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 10 | 0 | 10 | | 2016 | 7 | 1 | 8 | | 2017 | 4 | 0 | 4 | | 2018 | 4 | 1 | 5 | | 2019 | 5 | 2 | 7 | | 2020 | 7 | 2 | 9 | | 2021 | 4 | 0 | 4 | | 2022 | 6 | 0 | 6 | | 2023 | 3 | 0 | 3 | | 2024 | 2 | 0 | 2 | | 2025 | 3 | 0 | 3 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hemorrhagic Fever, Ebola" by people in Profiles.
-
Kpetigo AD, Alexandre M, Camara A, Beavogui A, Doumbia S, Kieh M, Leigh B, Sow S, Wittkop L, Soutthiphong AA, Berry IM, Fleck S, Akoo P, Hamze B, Watson-Jones D, Kuhn JH, Greenwood B, Richert L, Yazdanpanah Y, Lévy Y, Thiébaut R, Prague M, Lhomme E. Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial. PLoS Negl Trop Dis. 2026 Jan; 20(1):e0013950.
-
Chandrasekaran P, Berry IM, Callier V, Anthony SM, Hensley K, Kuhn JH, Shaw-Saliba K, Kennedy SB, Kieh M, Browne SM, Crozier I, Davey RT, Lane HC, Hensley LE, Follmann DA. Vector-Induced Humoral Responses After rVSV?G-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies. J Infect Dis. 2025 Oct 15; 232(4):1004-1014.
-
Worwa G, Davis CW, Klim SE, Turcinovic J, Agans KN, Borisevich V, Geisbert JB, Cross RW, Crane A, Holbrook MR, Sanchez-Lockhart M, Kugelman JR, Patino Galindo JA, Geisbert TW, Ahmed R, Kuhn JH, Saphire EO, Palacios G, Crozier I. Monotherapy with antibody 1C3 partially protects Ebola virus-exposed macaques. J Virol. 2025 07 22; 99(7):e0029625.
-
Hastie KM, Salie ZL, Ke Z, Halfmann PJ, DeWald LE, McArdle S, Grinyó A, Davidson E, Schendel SL, Hariharan C, Norris MJ, Yu X, Chennareddy C, Xiong X, Heinrich M, Holbrook MR, Doranz B, Crozier I, Kawaoka Y, Branco LM, Kuhn JH, Briggs JAG, Worwa G, Davis CW, Ahmed R, Saphire EO. Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane. Nat Commun. 2025 Feb 03; 16(1):1293.
-
Valayer S, Alexandre M, Prague M, Beavogui AH, Doumbia S, Kieh M, Greenwood B, Leigh B, Poupelin M, Schwimmer C, Sow SO, Berry IM, Kuhn JH, Fusco D, Cauwelaert ND, Watson-Jones D, Thiébaut R, Lévy Y, Yazdanpanah Y, Richert L, Lhomme E. Evaluation of waning of IgG antibody responses after rVSV?G-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial. Emerg Microbes Infect. 2025 Dec; 14(1):0.
-
Davey RT, Collins GL, Rouphael N, Poliquin G, McConnell R, Grubbs G, Moir SL, Langley JM, Teitelbaum M, Hewlett AL, McLellan SLF, Bhadelia N, Raabe VN, Mulligan MJ, Maljkovic Berry I, Dighero-Kemp B, Kurtz JR, Hensley LE, Dozier NCE, Marron LCB, DuChene A, Kuhn JH, Brown SK, Khurana S, Lane HC, Neaton JD. Safety and immunogenicity of a delayed booster dose of the rVSV?G-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial. Lancet Microbe. 2024 11; 5(11):100923.
-
Normandin E, Triana S, Raju SS, Lan TCT, Lagerborg K, Rudy M, Adams GC, DeRuff KC, Logue J, Liu D, Strebinger D, Rao A, Messer KS, Sacks M, Adams RD, Janosko K, Kotliar D, Shah R, Crozier I, Rinn JL, Melé M, Honko AN, Zhang F, Babadi M, Luban J, Bennett RS, Shalek AK, Barkas N, Lin AE, Hensley LE, Sabeti PC, Siddle KJ. Natural history of Ebola virus disease in rhesus monkeys shows viral variant emergence dynamics and tissue-specific host responses. Cell Genom. 2023 12 13; 3(12):100440.
-
Santus L, Sopena-Rios M, García-Pérez R, Lin AE, Adams GC, Barnes KG, Siddle KJ, Wohl S, Reverter F, Rinn JL, Bennett RS, Hensley LE, Sabeti PC, Melé M. Single-cell profiling of lncRNA expression during Ebola virus infection in rhesus macaques. Nat Commun. 2023 06 30; 14(1):3866.
-
Lee JH, Calcagno C, Feuerstein IM, Solomon J, Mani V, Huzella L, Castro MA, Laux J, Reeder RJ, Kim DY, Worwa G, Thomasson D, Hagen KR, Ragland DR, Kuhn JH, Johnson RF. Magnetic Resonance Imaging for Monitoring of Hepatic Disease Induced by Ebola Virus: a Nonhuman Primate Proof-of-Concept Study. Microbiol Spectr. 2023 06 15; 11(3):e0353822.
-
Kuhn JH, Schmaljohn CS. Of mice and Mike-An underappreciated Ebola virus disease model may have paved the road for future filovirology. Antiviral Res. 2023 02; 210:105522.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|